参芪扶正联合GP方案化疗治疗晚期NSLC临床对照研究

Shenqifuzheng combined with GP in the treatment of non-small cell lung carcinoma

目的：通过对比参芪扶正联合GP方案与GP方案分别治疗晚期NSLC的临床效果，探讨参芪扶正联合GP方案对于晚期NSLC治疗效果。方法回顾性分析2010年9月～2013年9月间我院收治的60例晚期非小细胞肺癌（NSCLC）患者为研究对象，其中采用参芪扶正联合GP方案化疗者30例（治疗组），单独采用GP方案化疗者30例（对照组）分析比较两组患者的近期临床疗效及其对患者生活质量的影响。结果治疗组客观有效率为53.3%，对照组有效率为26.7%，治疗组显著高于对照组（x2=4.4，P=0.03＜0.05）；治疗组生活质量提高者比例为50%显著多于对照组16.7%，且差别有统计学意义（x2=7.5，P=0.006＜0.05）；治疗组治疗期间发生白细胞下降4例，胃肠道反应7例，血小板下降6例；对照组发生白细胞下降12例，胃肠道反应6例，血小板下降7例。治疗组白细胞下降发生率显著低于对照组（x2=5.6，P=0.02＜0.05）。结论参芪扶正联合GP方案治疗晚期NSCLC可显著提高临床疗效，降低白细胞下降不良反应发生风险。

Objective The aim of this study was to evaluate the clinical efficacy of shenqifuzheng combined with GP regimen in the treatment of non-small cell lung carcinoma. Methods 60 cases with NSCLC was retrospectively analyzed in our hospital from 2010 to 2013.Of the included 60 cases,30 patients were treated with GP＋Shenqifuzheng and other 30 cases were treated with GP chemotherapy only.The clinical efficacy,life quality improvement and side effects were compared between the two groups. Results The objective response rate was 53.3% and 26.7% in the treatment and control group respectively,with statistical difference between the two groups（x^2=4.44,P=0.03 〈 0.05）;The life quality improvement in the treatment was much higher than that of control group（x2=7.5, P=0.006 〈 0.05）;The granulocytopenia risk in treatment group was much lower than that of control group（x2=5.6, P=0.02 〈 0.05）. Conclusion Shenqifuzheng combined with GP regimen chemotherapy can significant improve the clinical efficacy and decrease the risk of side effects in patients with non-small cell lung cancer.